Erratum: Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival (Journal of the National Cancer Institute (2018) 110:1 DOI: 10.1093/jnci/djx123);Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival

Journal of the National Cancer Institute

Volumn 110, Issue 1, 2018, Pages 97-108

  Mlecnik, Bernhard ^a,b,j   Van Den Eynde, Marc ^a,b,c,d,e,j   Bindea, Gabriela ^a,b,c,j   Church, Sarah E ^a,b,c,j   Vasaturo, Angela ^a,d   Fredriksen, Tessa ^a,b,d,j   Lafontaine, Lucie ^a,b,d,j   Haicheur, Nacilla ^f   Marliot, Florence ^a,b,c,f,j   Debetancourt, Daphné ^d,e   Pairet, Géraldine ^d,e   Jouret Mourin, Anne ^e   Gigot, Jean Francois ^e   Hubert, Catherine ^e   Danse, Etienne ^e   Dragean, Cristina ^e   Carrasco, Javier ⁱ   Humblet, Yves ^e   Valge Archer, Viia ^g   Berger, Anne ^a,b,c,h   Galon, Jérôme ^a,b,c,j   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Inovarion   (France)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g ASTRAZENECA   (United Kingdom)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ Grand Hopital de Charleroi   (Belgium)

^j CENTRE DE RECHERCHE DES CORDELIERS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; CD45 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSCORE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; SCORING SYSTEM; T LYMPHOCYTE; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; AGED; CD8+ T LYMPHOCYTE; CHEMISTRY; COLORECTAL NEOPLASMS; IMMUNOLOGY; LIVER NEOPLASMS; LIVER RESECTION; LUNG NEOPLASMS; LUNG RESECTION; LYMPHOCYTE COUNT; METASTASIS; METASTASIS RESECTION; MIDDLE AGED; PATHOLOGY; PREOPERATIVE PERIOD; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SECONDARY; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

AGED; ANTIGENS, CD20; ANTIGENS, CD3; ANTIGENS, CD45; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; METASTASECTOMY; MIDDLE AGED; NEOPLASM METASTASIS; PNEUMONECTOMY; PREOPERATIVE PERIOD; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85030417315     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djy034     Document Type: Erratum

References (50)

1. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol. 2009; 27(11):1829-1835.
2. Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619-2626.
3. Vigano L, Capussotti L, Lapointe R, et al. Early recurrence after liver resection for colorectal metastases: Risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6, 025 patients. Ann Surg Oncol. 2014;21(4): 1276-1286.
4. Blazer, DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344-5351.
5. Koi M, Garcia M, Choi C, et al. Microsatellite alterations with allelic loss at 9p24.2 signify less-aggressive colorectal cancer metastasis. Gastroenterology. 2016;150(4):944-955.
6. Mise Y, Zimmitti G, Shindoh J, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(3):834-842.
7. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299-304.
8. Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112(12):1921-1928.
9. Foersch S, Sperka T, Lindner C, et al. VEGFR2 signaling prevents colorectal cancer cell senescence to promote tumorigenesis in mice with colitis. Gastroenterology. 2015;149(1):177-189, e10.
10. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964.
11. Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138(4):1429-1440.
12. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610-618.
13. Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944-5951.
14. Berghoff AS, Fuchs E, Ricken G, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016;5(1):e1.
15. Galon J, Franck P, Marincola FM, et al. Cancer classification using the Immunoscore: A worldwide task force. J Transl Med. 2012;10(1):205.
16. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014; 232(2):199-209.
17. Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1.
18. Ferris RL, Galon J. Additional support for the introduction of immune cell quantification in colorectal cancer classification. J Natl Cancer Inst. 2016; 108(8):djw033.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2):228-247.
20. Altman DG, Lausen B, Sauerbrei W, et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86(11): 829-835.
21. Gerds TA, Schumacher M. Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biom J. 2006; 48(6):1029-1040.
22. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.
23. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61(1):92-105.
24. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal. 1998; 4(2):109-120.
25. Khan H, Khan N, Ahmad A, et al. Surgical management of metastatic colon cancer: A population-based analysis. J Geriatr Oncol. 2015;6(6):446-453.
26. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23(9):2038-2048.
27. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71(17):5670-5677.
28. Katz SC, Bamboat ZM, Maker AV, et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2013;20(3):946-955.
29. Pugh SA, Harrison RJ, Primrose JN, et al. T cells but not NK cells are associated with a favourable outcome for resected colorectal liver metastases. BMC Cancer. 2014;14:180.
30. Tanis E, Julie C, Emile JF, et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer. 2015;51(17):2708-2717.
31. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782-795.
32. Naxerova K, Jain RK. Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin Oncol. 2015;12(5):258-272.
33. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892.
34. Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346(6206):256-259.
35. Loes IM, Immervoll H, Sorbye H, et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer. 2016;139(3):647-656.
36. Sveen A, Loes IM, Alagaratnam S, et al. Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genet. 2016;12(7):e1006225.
37. Brunner SM, Kesselring R, Rubner C, et al. Prognosis according to histochemical analysis of liver metastases removed at liver resection. Br J Surg. 2014; 101(13):1681-1691.
38. Carrasco J, Gizzi M, Pairet G, et al. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. Br J Cancer. 2015;113(9):1298-1304.
39. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(21):2338-2344.
40. Valentini V, Minsky BD. Tumor regression grading in rectal cancer: Is it time to move forward? J Clin Oncol. 2014;32(15):1534-1536.
41. Galon J, Mlecnik B, Marliot F, et al. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1, 336 patients. J Clin Oncol. 2016;34(15 suppl):3500.
42. Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698-711.
43. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.
44. Angell H, Galon J. From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261-267.
45. Church SE, Galon J. Tumor microenvironment and immunotherapy: The whole picture is better than a glimpse. Immunity. 2015;43(4):631-633.
46. Galon J, Angell HK, Bedognetti D, et al. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity. 2013; 39(1):11-26.
47. Mlecnik B, Bindea G, Angell HK, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6(228):228ra37.
48. Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8(327):327ra26.
49. Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011;71(4):1263-1271.
50. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763.